Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Divi's Laboratories Ltd. (Unit II)
483
•Divi's Laboratories Ltd. (Unit II)•September 19, 2017

Divi's Laboratories Ltd. (Unit II) – FDA 483, Sep 19, 2017

Record Details

Divi's Laboratories Ltd., Unit II, located in Visakhapatnam, India, underwent an FDA inspection from June 29 to July 5, 2017. The inspection resulted in a Form 483 with three observations.

Observation 1 notes that the firm's quality control unit failed to ensure that drug products manufactured at the facility met the identity, strength, quality, and purity characteristics they purported or were represented to possess. Specifically, the firm released Active Pharmaceutical Ingredients (APIs) that were reprocessed multiple times without adequate justification or evaluation of the impact on the final product quality. There was no scientific rationale provided for the number of reprocessing steps, and the firm did not establish limits for the number of times a batch could be reprocessed. This indicates a lack of robust process control and validation.

Observation 2 identifies that the firm's quality unit responsibilities and procedures were not fully followed. The quality unit failed to adequately investigate out-of-specification (OOS) results and deviations. For instance, investigations into OOS results for impurities in certain APIs were closed without identifying a root cause or implementing effective corrective and preventive actions (CAPAs). This suggests a deficiency in the firm's deviation management and OOS investigation processes, potentially leading to the release of non-conforming products.

Observation 3 states that the firm failed to establish and follow adequate written procedures for production and process control designed to assure that the drug products have

Company
Divi's Laboratories Ltd. (Unit II)
Inspection date
September 19, 2017
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Erika V. Butler (Compliance Officer / Investigator)
View Company Profile

ID · 85a9b4a5-0956-4d81-8d9f-f4a55c288d6b

Violation Codes4
21 CFR 21021 CFR 21121 CFR 331(c)21 U.S.C. 324(a)(4)

Full citation text and observation details available on the Dashboard.

Other documents for Divi's Laboratories Ltd. (Unit II)
  • 483 - 2024-07-19July 19, 2024
  • 483 - 2016-12-06December 6, 2016

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Divi's Laboratories Ltd. (Unit II)
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.